Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol

[1]  U. Diczfalusy,et al.  Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians , 2011, The Pharmacogenomics Journal.

[2]  L. Bertilsson,et al.  4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. , 2011, British journal of clinical pharmacology.

[3]  A. D. Rodrigues,et al.  Does the Long Plasma Half‐Life of 4β‐Hydroxycholesterol Impact Its Utility as a Cytochrome P450 3A (CYP3A) Metric? , 2010, Journal of clinical pharmacology.

[4]  U. Fuhr,et al.  Plasma 4β‐Hydroxycholesterol: An Endogenous CYP3A Metric? , 2009, Clinical pharmacology and therapeutics.

[5]  M. Abdollahi,et al.  On the Relation of Oxidative Stress in Delivery Mode in Pregnant Women; A Toxicological Concern , 2009, Toxicology mechanisms and methods.

[6]  A. Nabhan,et al.  Impact of intrapartum factors on oxidative stress in newborns , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[7]  L. Bertilsson,et al.  Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β‐Hydroxycholesterol , 2008, Clinical pharmacology and therapeutics.

[8]  B. Kirby,et al.  Effects of Pregnancy on CYP3A and P‐glycoprotein Activities as Measured by Disposition of Midazolam and Digoxin: A University of Washington Specialized Center of Research Study , 2008, Clinical pharmacology and therapeutics.

[9]  G. Tucker,et al.  Development of CYP2D6 and CYP3A4 in the First Year of Life , 2008, Clinical pharmacology and therapeutics.

[10]  L. Bertilsson,et al.  4&bgr;-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians , 2008, Pharmacogenetics and genomics.

[11]  H. Schwilden,et al.  Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation , 2007, European Journal of Clinical Pharmacology.

[12]  G. Kearns,et al.  Ontogeny of Dextromethorphan O‐ and N‐demethylation in the First Year of Life , 2007, Clinical pharmacology and therapeutics.

[13]  I. Papassotiriou,et al.  Maternal‐neonatal 8‐hydroxy‐deoxyguanosine serum concentrations as an index of DNA oxidation in association with the mode of labour and delivery , 2007, Acta obstetricia et gynecologica Scandinavica.

[14]  Jaran Eriksen,et al.  CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population , 2006, Pharmacogenetics and genomics.

[15]  M. Kılınç,et al.  Relationship between Oxidative Stress in Cord Blood and Route of Delivery , 2005, Fetal Diagnosis and Therapy.

[16]  D. Lichtenberg,et al.  Oxidative stress in the fetal circulation does not depend on mode of delivery. , 2005, American journal of obstetrics and gynecology.

[17]  S. Caritis,et al.  Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. , 2005, American journal of obstetrics and gynecology.

[18]  M. Galteau,et al.  Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals , 2003, European Journal of Clinical Pharmacology.

[19]  Ronald N. Hines,et al.  Developmental Expression of the Major Human Hepatic CYP3A Enzymes , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  K. Stȩpniewska,et al.  Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil , 2003, European Journal of Clinical Pharmacology.

[21]  S. Hayashi,et al.  Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women , 2003, AIDS.

[22]  T. Cresteil,et al.  Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[23]  B. van der Wildt,et al.  Umbilical glutathione levels are higher after vaginal birth than after cesarean section , 2003, Journal of perinatal medicine.

[24]  I. Björkhem,et al.  Metabolism of 4β-Hydroxycholesterol in Humans* , 2002, The Journal of Biological Chemistry.

[25]  L. Bertilsson,et al.  Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. , 2001, The Journal of biological chemistry.

[26]  I. Miyakawa,et al.  The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N‐acetyltransferase activities in humans , 2001, Clinical pharmacology and therapeutics.

[27]  M. Eichelbaum,et al.  CYP3A genetics in drug metabolism , 2001, Nature Medicine.

[28]  A. Nafziger,et al.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.

[29]  M. S. Ching,et al.  Fetal hepatic drug elimination. , 1999, Pharmacology & therapeutics.

[30]  M. Wadelius,et al.  Induction of CYP2D6 in pregnancy , 1997, Clinical pharmacology and therapeutics.

[31]  U. Diczfalusy,et al.  The oxysterols cholest-5-ene-3β,4α-diol, cholest-5-ene-3β,4β-diol and cholestane-3β,5α,6α-triol are formed during in vitro oxidation of low density lipoprotein, and are present in human atherosclerotic plaques , 1996 .

[32]  M. Kilby,et al.  Fetal and maternal lipoprotein metabolism in human pregnancy. , 1995, Clinical science.

[33]  G. Watts,et al.  Serum lipids, lipoproteins and apolipoproteins in pregnant non-diabetic patients. , 1994, Journal of clinical pathology.

[34]  A. Chobanian,et al.  Body cholesterol metabolism in man. II. Measurement of the body cholesterol miscible pool and turnover rate. , 1962, The Journal of clinical investigation.

[35]  L. Bertilsson,et al.  4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. , 2009, British journal of clinical pharmacology.

[36]  T. Silberstein,et al.  Oxidative stress as determined by glutathione (GSH) concentrations in venous cord blood in elective cesarean delivery versus uncomplicated vaginal delivery , 2007, Archives of Gynecology and Obstetrics.

[37]  G. Anderson.  Pregnancy-Induced Changes in Pharmacokinetics , 2005, Clinical pharmacokinetics.

[38]  L. Rivory,et al.  The Erythromycin Breath Test For the Prediction of Drug Clearance , 2001, Clinical pharmacokinetics.

[39]  S. Sekiya,et al.  Comparison of urinary 6β-hydroxycortisol/cortisol ratio between neonates and their mothers , 1999 .

[40]  C. Regårdh,et al.  The rhesus monkey as a model for studies of pregnancy induced changes in metoprolol metabolism. , 1990, Pharmacology & toxicology.